secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2026-11-02T12:39:46+00:00
Accession:  0001213900-26-114665
Event type: earnings
Sentiment:  positive
Materiality: 0.62
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

CorMedix reaffirms 2026 revenue guidance of $325-345M; CMS sets Q1 2027 DefenCath Add-on at $8.32 per session
--------------------------------------------------------------------------------

- Unaudited cash and cash equivalents of approximately $355 million as of September 30, 2026; full Q3 results to be discussed on a November 12, 2026 call.
- Reaffirmed August 2026 full-year 2026 total revenue guidance of $325 million to $345 million.
- CMS's October 28, 2026 ESRD PPS final rule set the Q1 2027 DefenCath post-TDAPA Add-on at $8.32 per dialysis session, 3.5x the current $2.37 rate.
- CorMedix expects the Add-on to decline in Q2 2027 versus Q1, then rise in Q3 and/or Q4, with the full-year 2027 average above 2x the current $2.37.
- Company said it provided no utilization or pricing data to any large dialysis organization; third-party 2027 Add-on projections are not CorMedix guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390026114665/0001213900-26-114665-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390026114665/ea0310445-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-114665

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer